Isis Pharmaceuticals | Press Releases

** Even though the press releases remain on our site, we do not update information of individual releases to reflect subsequent developments. Content and information present in each press release was factually accurate on the issue date. **

2003
Mar. 17	ISIS PHARMACEUTICALS AND ELI LILLY AND COMPANY ANNOUNCE RESULTS OF AFFINITAK™ PHASE III CLINICAL TRIAL IN NON-SMALL CELL LUNG CANCER
Feb. 11	ISIS PHARMACEUTICALS REPORTS FINANCIAL RESULTS AND HIGHLIGHTS FOR THE YEAR 2002 - Company Achieves Record Revenues in 2002
Feb. 10	ISIS PHARMACEUTICALS EARNS SECOND MILESTONE IN AMGEN ANTISENSE DRUG DISCOVERY COLLABORATION
Jan.22	ISIS PHARMACEUTICALS ENTERS INTO TARGET VALIDATION AGREEMENT WITH PFIZER
Jan.16	ISIS PHARMACEUTICALS AND ATUGEN AG ENTER PATENT LICENSE AGREEMENT

2002
Dec. 23	ISIS PHARMACEUTICALS REACQUIRES ISIS 113715 TYPE 2 DIABETES DRUG FROM MERCK - Isis to initiate Phase I trials of antisense drug for Type 2 diabetes
Dec. 18	ISIS PHARMACEUTICALS REPORTS NEW DATA FROM PHASE II CLINICAL TRIAL OF ISIS 2503 PLUS CHEMOTHERAPY IN PANCREATIC CANCER - Study Results Support Further Development of Antisense Compound
Dec.16	ONCOGENEX TECHNOLOGIES AND ISIS PHARMACEUTICALS ACHIEVE ALLIANCE MILESTONE: INITIATE PHASE I CLINICAL TRIAL OF ANTISENSE DRUG IN PROSTATE CANCER
Dec.11	ISIS PHARMACEUTICALS AND GLAXOSMITHKLINE ENTER INTO TARGET VALIDATION AGREEMENT
Dec. 6	ISIS PHARMACEUTICALS STATEMENT REGARDING UBS WARBURG REPORT - Isis and Lilly Remain Blinded to Affinitak™ Phase III Clinical Trial
Nov. 21	ISIS PHARMACEUTICALS INITIATES PHASE II CLINICAL TRIAL OF ALICAFORSEN, ISIS 2302, IN PATIENTS WITH ULCERATIVE COLITIS
Nov. 12	NEW DATA ON CAPSULE FORM OF ISIS 104838 DEMONSTRATE ANTISENSE DRUGS CAN BE ADMINISTERED ORALLY - Orasense Joint Venture Makes Fundamental Advance in Antisense Technology
Nov. 6	ISIS PHARMACEUTICALS REPORTS THIRD QUARTER AND YEAR TO DATE 2002 FINANCIAL RESULTS
Nov. 6	ISIS PHARMACEUTICALS AND ELAN CORPORATION CONCLUDE COLLABORATION IN HEPASENSE JOINT VENTURE AND RESTRUCTURE ORASENSE COLLABORATION - Isis Regains Rights to ISIS 14803 for HCV
Nov. 5	NEW PHASE II DATA CONFIRM ISIS 14803 PRODUCES SIGNIFICANT VIRAL LEVEL REDUCTIONS IN PATIENTS WITH DRUG - RESISTANT HEPATITIS C - Clinical Investigators Report Data from Two Clinical Trials
Oct. 21	ALICAFORSEN (ISIS 2302) IMPROVES POTENTIAL FOR RESPONSES AND REMISSIONS IN PATIENTS WITH CROHN'S DISEASE - Isis to provide conference call update on clinical programs, including status of the two Phase III trials of Affinitac that remain blinded
Oct. 1	ISIS PHARMACEUTICALS TO MANUFACTURE AFFINITAC™ FOR ELI LILLY AND COMPANY FOR INITIAL COMMERCIALIZATION
Sep. 18	ISIS RECEIVES 1,000th PATENT - Company Achieves Major Innovation Milestone in RNA-based Drug Discovery and Development
Sep. 16	ISIS PHARMACEUTICALS AND SEQUITUR SETTLE PATENT INFRINGEMENT LAWSUIT - Sequitur Licenses Isis' Intellectual Property for Functional Genomics
Aug. 15	ISIS PHARMACEUTICALS AND HYBRIDON CANCEL REMAINING RECIPROCAL FINANCIAL OBLIGATIONS FROM INTELLECTUAL PROPERTY TRANSACTION
Aug. 14	ISIS PHARMACEUTICALS ACHIEVES MILESTONE IN AMGEN ANTISENSE DRUG DISCOVERY COLLABORATION
Jul. 30	ISIS PHARMACEUTICALS REPORTS SECOND QUARTER 2002 HIGHLIGHTS AND FINANCIAL RESULTS - Company Reports Increased Revenue and Strengthened Balance Sheet
Jul. 3	ISIS PHARMACEUTICALS CONTINUES TO STRENGTHEN BALANCE SHEET BY PREPAYING $19.7 MILLION OF 12% CONVERTIBLE DEBT HELD BY ELAN — Prepayment Reduces Isis' Potential Dilution by 2.2 Million Shares
Jun. 25	ISIS PHARMACEUTICALS INITIATES EUROPEAN PHASE III CLINICAL TRIAL OF ALICAFORSEN, ISIS 2302, IN CROHN'S DISEASE
Jun. 18	ISIS AND LILLY BROADEN ANTISENSE ALLIANCE TO INCLUDE DISCOVERY OF CANCER TREATMENTS
Jun. 11	SPENCER R. BERTHELSEN, M.D., F.A.C.P., ELECTED TO ISIS PHARMACEUTICALS' BOARD OF DIRECTORS
May 29	ISSUANCE OF PIVOTAL PATENT PROVIDES ISIS PHARMACEUTICALS THERAPEUTIC CONTROL OVER THIRD-GENERATION ANTISENSE CHEMISTRY - Isis is Exclusive Therapeutic Licensee of PNA Chemistry
May21	ISIS PHARMACEUTICALS EXPANDS THERAPEUTIC POTENTIAL OF ANTISENSE TECHNOLOGY TO CARDIOVASCULAR DISEASE — First Antisense Drug Candidate from Heart Disease Program Reduces Cholesterol
May 20	NEW AFFINITAC™ DATA IN NON-SMALL CELL LUNG CANCER PRESENTED AT ASCO — Phase II Trials of Targeted Antisense Drug Demonstrate Activity in Both Chemotherapy Naïve and Extensively Pretreated Patients
Apr. 25	ISIS PHARMACEUTICALS ANNOUNCES PRICING OF CONVERTIBLE SUBORDINATED NOTES
Apr. 25	ISIS PHARMACEUTICALS ACHIEVES $3.75 MILLION DEVELOPMENT MILESTONE IN HEPASENSE JOINT VENTURE WITH ELAN CORPORATION
Apr. 24	ISIS PHARMACEUTICALS TO MAKE EARLY PAYMENT OF $74 MILLION OF 14% SENIOR SUBORDINATED DEBT - Company Plans to use Proceeds from Convertible Debt Offering to Retire Notes
Apr. 23	ISIS PHARMACEUTICALS ANNOUNCES CONVERTIBLE DEBT OFFERING
Apr. 23	ISIS PHARMACEUTICALS REPORTS FIRST QUARTER 2002 HIGHLIGHTS AND FINANCIAL RESULTS - Company Reports Increased Revenue and Decreased Net Operating Loss
Apr. 22	ISIS PHARMACEUTICALS AND MERCK EXTEND HEPATITIS C DRUG DISCOVERY COLLABORATION FOR A SECOND TIME - New Agreement Marks Five Years of Collaborative Drug Discovery Research in Chronic Disease
Apr. 11	Isis Pharmaceuticals and Lilly's Strategic Alliance Voted Breakthrough Alliance of 2002
Apr. 10	ISIS PHARMACEUTICALS REPORTS PRELIMINARY PHASE II DATA ON ISIS 2503 PLUS CHEMOTHERAPY IN PANCREATIC CANCER - Survival Results at Planned Interim Analysis Exceed Clinical Expectations; Trial Continues
Apr. 4	ISIS PHARMACEUTICALS' IBIS THERAPEUTICS DIVISION AWARDED NEW $2.4 MILLION GOVERNMENT CONTRACT TO ADVANCE ITS ANTIBACTERIAL DRUG DISCOVERY PROGRAM - Ibis' Biological Warfare Countermeasure Research Transitions to USAMRIID
Apr. 3	ISSUANCE OF KEY SECOND-GENERATION ANTISENSE PATENT FURTHER STRENGTHENS ISIS’ INTELLECTUAL PROPERTY ESTATE
Apr. 2	ISIS PHARMACEUTICALS ANNOUNCES ADOPTION OF SECURITIES TRADING PLAN UNDER SEC RULE 10b5-1